Physician profile

Marque A Hunter

Pulmonary Disease · Lubbock, TX

NPI 1568485258

$14,159.99

in general payments reported to CMS, 2019-2025

40 companies · $1,891 in 2025

The $1,891 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$7,147.29

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $3,695.50 2019-2025 Trelegy Ellipta, Nucala, Arexvy
Boehringer Ingelheim Pharmaceuticals, INC. $1,802.69 2019-2025 Ofev, Spiriva Respimat, Jascayd
Astrazeneca Pharmaceuticals LP $1,543.68 2019-2025 Fasenra, Airsupra, Breztri
Grifols USA, LLC $1,073.88 2019-2025 Prolastin-C Liquid
Amgen INC. $714.77 2022-2025 Tezspire, Tavneos
Mylan Specialty L.P. $584.20 2019-2024 Yupelri
Baxter Healthcare $456.29 2022-2024 Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care
Regeneron Healthcare Solutions, INC. $439.11 2019-2025 Dupixent
Genzyme Corporation $427.76 2020-2025
Actelion Pharmaceuticals US, INC. $390.71 2019-2024 Opsumit
Janssen Pharmaceuticals, INC $331.78 2019-2024 Xarelto
Takeda Pharmaceuticals U.S.A., INC. $294.95 2020-2024 Glassia
Insmed, INC. $235.01 2019-2025 Arikayce, Brinsupri
Pfizer INC. $195.98 2023-2025
Verona Pharma, INC. $191.24 2025 Ohtuvayre
Show all 40 companies
CompanyGeneral paymentsYearsTop products
Harmony Biosciences LLC $190.72 2022
Abiomed $187.62 2023-2024 Impella
United Therapeutics Corporation $162.76 2019-2025 Tyvaso, Tyvaso
Inspire Medical Systems, INC. $157.85 2019-2024 Inspire
Merck Sharp & Dohme LLC $137.92 2019-2024 Keytruda, Winrevair
Abbvie INC. $124.66 2021-2025
Genentech USA, INC. $95.54 2019-2024 Xolair
Mallinckrodt Hospital Products INC. $93.54 2020-2025 Terlivaz
Nabriva Therapeutics, Plc $88.38 2021-2022
Medivance, INC. $74.68 2021
Viatris Specialty LLC $71.35 2025 Yupelri
Gilead Sciences, INC. $70.84 2021-2022
Philips North America LLC $61.74 2021-2023
Inari Medical, INC. $39.85 2024 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Shire North American Group INC $33.26 2019
Inogen, INC. $25.79 2022-2024
Axsome Therapeutics, INC. $25.14 2025 Sunosi
Ucb, INC. $23.45 2022
Bayer Healthcare Pharmaceuticals INC. $23.43 2020
Boston Scientific Corporation $18.22 2023 Exalt Model D
Advanced Respiratory, INC $17.79 2021
Movair INC $17.25 2025 Luisa
Ani Pharmaceuticals, INC. $14.06 2023 Purified Cortrophin Gel
Sanofi-Aventis U.S. LLC $13.68 2021
Allergan, INC. $12.92 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Marque A Hunter

$14,159.99

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $1,891 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/116489/marque-a-hunter

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.